<DOC>
	<DOCNO>NCT02292784</DOCNO>
	<brief_summary>The primary objective study assess safety outcomes infant child expose retosiban comparator utero plan Phase III spontaneous preterm labor ( SPTL ) treatment study , provide assurance treatment associate significant adverse outcome early childhood . The enrolled infant child follow pre-specified interval reach 5 year chronological age . This study require medical intervention study visit investigational site , instead , parent legal guardian prompt certain time point complete developmental questionnaire data child 's health status via electronic device . Data collect infant child follow study manage centralize research coordinate center ( RCC ) . Regionally base pediatrician serve study principal investigator ( refer RCC-PIs ) study . All communication RCC-PI parent/legal guardian child 's health care provider ( HCP ) occur remotely ; clinic visit .</brief_summary>
	<brief_title>Follow Study Assess Long Term Safety Outcomes Infants Children Born Mothers Participating Retosiban Treatment Studies</brief_title>
	<detailed_description />
	<mesh_term>Obstetric Labor , Premature</mesh_term>
	<mesh_term>Atosiban</mesh_term>
	<mesh_term>Vasotocin</mesh_term>
	<criteria>Mother randomly assign dose ( retosiban comparator ) 1 Phase III SPTL retosiban clinical study . Infant alive 28 day post EDD . Written inform consent obtain parent ( ) legal guardian ( ) infant . The parent/legal guardian participant age 12 17 year must also provide write agreement infant participate study require applicable regulatory country state requirement . There formal exclusion criterion participation .</criteria>
	<gender>All</gender>
	<minimum_age>10 Weeks</minimum_age>
	<maximum_age>20 Weeks</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>infant</keyword>
	<keyword>retosiban</keyword>
	<keyword>Preterm Labor</keyword>
	<keyword>long-term safety follow-up</keyword>
</DOC>